» Authors » Thomas M K So

Thomas M K So

Explore the profile of Thomas M K So including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 464
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ching J, Chan K, Lee E, Xu M, Ting C, So T, et al.
J Infect Dis . 2010 May; 201(12):1899-908. PMID: 20462354
Myxovirus resistance A (MxA) is an antiviral protein induced by interferon alpha and beta (IFN-alpha, IFN-beta) that can inhibit viral replication. The minor alleles of the -88G>T and -123C>A MxA...
2.
Lam E, Lam C, Lai C, Yuen M, Fong D, So T
Health Qual Life Outcomes . 2009 Jun; 7:52. PMID: 19500349
Background: Few studies have evaluated the health-related quality of life (HRQOL) of Southern Chinese with chronic hepatitis B (CHB) infection. Aim: To evaluate the HRQOL of Chinese patients at different...
3.
Buster E, Flink H, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al.
Gastroenterology . 2008 Jul; 135(2):459-67. PMID: 18585385
Background & Aims: The aim of this study was to evaluate the long-term sustainability of response in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B treated with pegylated...
4.
van Zonneveld M, Zondervan P, Cakaloglu Y, Simon C, Akarca U, So T, et al.
Liver Int . 2006 Apr; 26(4):399-405. PMID: 16629642
Background: The effect of pegylated interferon or its combination with lamivudine on liver histology of patients with chronic hepatitis B (CHB) is unknown. In a double-blinded, randomized, multi-center study we...
5.
Janssen H, van Zonneveld M, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y, et al.
Lancet . 2005 Jan; 365(9454):123-9. PMID: 15639293
Background: Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained...